Quantcast

Latest Olanzapine Stories

2009-01-07 17:12:00

INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults. Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of the NDA. Per the agency's...

2008-12-11 05:30:00

NEW YORK, Dec. 11 /PRNewswire-FirstCall/ -- -- Innovation and Patient-Centered Approach Expected to Drive Future Success -- Lilly Climbs into Top 10 Pharmaceutical Companies in Worldwide Sales and Is Fastest Growing in U.S. -- FIPNet Strategy Expands Global Reach and Improves R&D Productivity -- Company Aims to Reduce Cost of Bringing New Medicine to Market from $1.2 Billion to $800 Million by 2010. -- R&D Pipeline Boasts Unprecedented 59...

2008-11-13 09:00:07

Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the third quarter ended September 30, 2008. For the third quarter of 2008, Corcept reported a net loss of $5.6 million, or $0.11 per share, compared to a net loss of $3.4 million, or $0.09 per share, for the third quarter of 2007. For the first nine months of 2008, the company reported a net loss of $13.9 million, or $0.30 per share, compared to a net loss of $7.4 million, or $0.23 per share, for the same...

2008-10-23 06:00:27

INDIANAPOLIS, Oct. 23 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced financial results for the third quarter of 2008. Due to significant strategic actions taken by the company in 2008, financial results are presented on both a reported basis and a pro forma non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all sales and expenses recognized by the company during the period. Pro forma non-GAAP...

2008-10-21 09:00:54

INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it is in advanced discussions to resolve the ongoing investigations led by the U.S. Attorney's Office for the Eastern District of Pennsylvania (EDPA) related to past U.S. marketing and promotional practices for its antipsychotic medication Zyprexa(R) (olanzapine). As a result, the company will record in the third quarter of 2008 a charge of $1.415 billion, or $1.29 per share. The Government's...

2008-10-13 03:00:34

By Wall, J K Lilly Endowment Inc. is still on its journey to sell off $2 billion of its Eli Lilly and Co. shares. But after a slow start and a few stops for rest, it may take a little longer to get there than originally thought. The endowment, the single largest holder of Lilly stock, announced its plan to diversify its holdings back in July 2006. For nearly 70 years, the not-for-profit held its wealth almost exclusively in the pharmaceutical company's stock. So far, it has sold off...

2008-10-08 09:00:50

Drugmaker Eli Lilly & Co. cleared a legal cloud hanging over its top-selling drug Zyprexa, an antipsychotic medication, when it announced a $62 million settlement Tuesday. Lilly agreed to pay 32 states and Washington to resolve an investigation into the company's marketing practices. (c) 2008 Virginian - Pilot. Provided by ProQuest LLC. All rights Reserved.

2008-10-08 09:00:50

Eli Lilly and Company has resolved a multi-state investigation involving 32 states and the District of Columbia related to the sales, marketing and promotion of its antipsychotic medication Zyprexa. While there is no finding that Lilly has violated any provision of the state laws under which the investigations were conducted, the company said that it will pay $62 million to be divided among the settling states. This payment will result in a charge in the third quarter of $0.04 per share....

2008-10-07 09:00:55

INDIANAPOLIS, Ind., Oct. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has resolved a multi-state investigation involving 32 states and the District of Columbia (DC) related to the sales, marketing and promotion of its antipsychotic medication Zyprexa(R) (olanzapine). "We believe all of the parties involved share an interest in putting this dispute behind us," said Robert A. Armitage, Lilly's senior vice president and general counsel. "From our standpoint, it's...

2008-10-07 06:00:44

By Julie Schmit Drugmaker Eli Lilly agreed Monday to pay $6.5 billion for biotech-drug maker ImClone Systems, beating an offer by Bristol-Myers Squibb and boosting its stable of cancer drugs. The all-cash deal, which has been approved by both companies' boards, values ImClone at $70 a share. That's a 51% premium to ImClone's closing price on July 30, the day before Bristol's $60-a-share offer was made public. That was later boosted to $62 a share. Lilly's shares fell 7% Monday...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related